DNA extraction from the spleen in human leukocyte antigen matching

doi:10.3969/j.issn.2095-4344.2013.05.002

Abstract

Abstract:

BACKGROUND: Whether human leukocyte antigen matching results are accurate or not may directly affect the pairing choice between the donors and recipients. Moreover, the quality of the matching samples may influence the pros and cons of the results.
OBJECTIVE: To establish an experimental technology platform for DNA extraction from the spleen in human leukocyte antigen matching.
METHODS: Lymphocytes were isolated and DNA was extracted from the spleen for the human leukocyte antigen matching, compared with DNA extracted from the whole blood which was normal peripheral blood or hematolytic sample.
RESULTS AND CONCLUSION: Intact electrophoretogram of DNA extracted from the spleen and normal peripheral blood was obtained after amplification and electrophoresis, and the electrophoretogram of DNA extracted from spleen was clearer than that extracted from the normal peripheral blood. However, the intact electrophoretogram of DNA extracted from hematolytic sample was not obtained. An experimental technology platform for DNA extraction from the spleen in human leukocyte antigen matching has been successfully established.

Key words: organ transplantation, transplantation and immunology, human leukocyte antigen, matching, rejection, spleen, transplantation, degree of compatibility, hemolysis, polymerase chain reaction, photographs-containing paper of organ transplantation

CLC Number:

R318

Li Hai-bin, Guo Hai-ge, Cai Wen-e, Qin Yin-hong, Sun Xu-yong. DNA extraction from the spleen in human leukocyte antigen matching[J]. Chinese Journal of Tissue Engineering Research, 2013, 17(5): 769-776.

Figures/Tables 3

References

[1] Sharma A, Armstrong AE, Posner MP, et al. Graft-versus-host disease after solid organ transplantation: A single center experience and review of literature. Ann Transplant. 2012; 17(4):133-139.

[2] Tait BD, Süsal C, Gebel HM, et al. Consensus Guidelines on the Testing and Clinical Management Issues Associated With HLA and Non-HLA Antibodies in Transplantation. Transplantation. 2013;95(1):19-47.

[3] Otten HG, Calis JJ, Ke?mir C, et al. Predicted indirectly recognizable HLA epitopes presented by HLA-DR correlate with the de novo development of donor-specific HLA IgG antibodies after kidney transplantation. Hum Immunol. 2012 Dec 8.

[4] Jia BX, Ma WR, Tian Y. Shoudu Yike Daxue Xuebao. 2011; 32(6):838-842.贾保祥,马威然,田野.亲属肾移植患者术后肾功能与HLA配型和PRA相关性研究[J]. 首都医科大学学报,2011,32(6): 838-842.

[5] Xu WZ, Jia BX, Yang HJ, et al. Guoji Waikexue Zazhi. 2011; 38(1):25-27.徐婉珍,贾保祥,杨慧静,等.222例活体肾移植供受者HLA分型配合率的分析[J]. 国际外科学杂志,2011,38(1):25-27.

[6] Leventhal J, Abecassis M, Miller J, et al. Tolerance Induction in HLA Disparate Living Donor Kidney Transplantation by Donor Stem Cell Infusion: Durable Chimerism Predicts Outcome. Transplantation. 2013;95(1):169-176.

[7] Ro H, Min SI, Yang J, et al. Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation. Ther Drug Monit. 2012;34(6):680-685.

[8] Paramesh A S, Zhang R, Baber J, et al. The effect of HLA mismatch on highly sensitized renal allograft recipients. Clin Transplant. 2010;24(6):E247-E252.

[9] Jia BX, Tang YW, Ma WR, et al. Guoji Jianyan Yixue Zazhi. 2011;32(16):1802-1804.贾保祥,唐雅望,马威然,等. HLA配型和PRA对移植肾功能的影响研究[J]. 国际检验医学杂志,2011,32(16):1802-1804.

[10] Jia JX, Zhang XD. Guoji Jianyan Yixue Zazhi. 2011; 32(16): 1809-1810, 1813.贾佳熹,张小东.活体亲属肾移植患者HLA配型配合率的分析[J]. 国际检验医学杂志,2011,32(16):1809-1810, 1813.

[11] Huang XE,, Li LY, Fan LP, et al. Zhonghua Qiguan Yizhi Zazhi. 2004;25(5):298-301.黄先恩,李留洋,范礼佩,等. 影响致敏患者移植肾存活的危险因素分析[J]. 中华器官移植杂志,2004,25(5):298-301.

[12] Li XK, Sun WY, Zhang SX. Haerbin YIke Daxue Xuebao. 2010;44(5):484-488.李兴库,孙文英,张镯潇. 高致敏肾移植患者的HLA等位基因选择性配型的临床意义[J]. 哈尔滨医科大学学报,2010,44(5): 484-488.

[13] Zhou YC. Zhonghua Yizhi Zazhi(Dianziban). 2011;5(1): 63-66.周永昌. HLA抗原系统与移植临床[J]. 中华移植杂志(电子版), 2011,5(1):63-66.

[14] Wu XD, Yang SJ, Cui YN, et al. Zhongguo Shiyan Zhenduanxue. 2005;5:95-96.吴晓冬,杨绍娟,崔亚南,等. HLA-Ⅰ、Ⅱ类PCR-SSP基因分型与血清学抗原分型在移植配型中的比较应用[J]. 中国实验诊断学, 2005(5):95-96.

[15] Zhu JF, Zhang YY, Qi HG. Disi Junyi Daxue Xuebao. 2009; 30(21):2396.朱建锋,张奕奕,祈洪刚. HLA配型与肾移植术后早期排斥反应的关系[J]. 第四军医大学学报,2009,30(21):2396.

[16] Ren Y, Yang YR. Xibao yu Fenzi Mianyixue Zazhi. 2007;11: 1080-1082.任雨,杨亦荣. HLA抗体筛选技术的最新进展及其在器官移植中的应用[J]. 细胞与分子免疫学杂志,2007,11:1080-1082.

[17] Liang DY, Yue Zj. Guowai Yixue:YIzhi yu Xueye Jinghua Fence. 2005;2:8-11.梁东彦,岳中瑾.再次肾移植[J]. 国外医学:移植与血液净化分册, 2005,2:8-11.

[18] Liu XY, Luo M,Xiao LL, et al. Shiyong Yufang Yixue. 2012; 19(8):1125-1127.刘小友,罗敏,肖露露,等. NK受体KIR及其HLA配体对肾移植急性排斥反应的作用[J]. 实用预防医学,2012,19(8): 1125-1127.

[19] Han ZM, Xia LL, Yu LX, et al. Xiandai Miniao Waike Zazhi. 2010;15(02):110-113.韩志明,肖露露,于立新,等. 南方汉族等候肾移植终末期肾功能衰竭患者HLA基因多态性分析[J]. 现代泌尿外科杂志, 2010, 15(02):110-113.

[20] Jia BX, Ma WY, Tian Y. ZHonghua Weishengwuxue he Mianyixue Zazhi. 2012;32(04):315-317贾保祥,马威然,田野. HLA配型和DSA对移植肾功能的影响研究[J]. 中华微生物学和免疫学杂志,2012,32(04):315-317

[21] Xue Wj, Hou J, Tian PX, et al. Zhonghua QIguan Yizhi Zazhi. 2010;31(11):654-656.薛武军,侯军,田普训,等. HLA配型对肾移植长期效果的影响(2508例次总结)[J].中华器官移植杂志,2010,31(11):654-656.

[22] Yu LX, Xiao F, Xiao LL, et al. Nanfang Yike Daxue Xuebao. 2010;30(2):288-291.于立新,肖飞,肖露露,等. KIR及其HLA配体与肾移植急性排斥反应的关系[J]. 南方医科大学学报,2010,30(2):288-291.

[23] Ling JY. Shanghai Jiaotong Daxue Xuebao:Yixueban. 2006; 26(6):561-562.凌建煜. 同种异体肾移植[J]. 上海交通大学学报:医学版, 2006, 26(6):561-562.

[24] Wang CA, Han L. Zhengzhou Daxue Xuebao:Yixueban. 2004; 39(5):872.王长安,韩林. 人异体肾移植HLA配型291例次[J]. 郑州大学学报:医学版,2004,39(5):872.

[25] Yang SJ, Xue LJ, Wu XD, et al. Zhongguo Mianyixue Zazhi. 2006;22(9):878-879.杨绍娟,薛丽娟,吴晓冬,等. HLA配型、交叉反应组(CREGs)误配率与肾移植术后早期排斥反应的关系[J]. 中国免疫学杂志, 2006, 22(9):878-879.

[26] Jia BX, Ma WR, Tian Y. Zhongguo Weishengwu he Mianyixue Zazhi. 2011;31(2):112.贾保祥,马威然,田野. 活体亲属肾移植患者HLA配型配合率的分析[J]. 中华微生物学和免疫学杂志,2011,31(2):112.

[27] Sun XY, XIao LL, Wen N, et al. Guangxi Yike Daxue Xuebao. 2010;27(3):394-396.孙煦勇,肖露露,文宁,等. 氨基酸残基配型策略在高致敏尿毒症患者肾移植中的应用研究[J]. 广西医科大学学报,2010,27(3): 394-396.

[28] Chen NY, Zhang W, Wang W, et al. Zhejiang Yixue. 2011; 33(12):1831-1832, 1841.陈男英,章伟,王炜,等. HLA-B新等位基因B*51:02:03的确认和分析[J]. 浙江医学,2011,33(12):1831-1832, 1841.

[29] Jiao LX, Yang F, Han Y, et al. Zhongguo Zuzhi Gongcheng Yanjiu. 2012;16(18):3345-3348.焦立新,杨帆,韩瑜,等. 吉林汉族人群HLA-A高分辨基因的多态性分析[J]. 中国组织工程研究,2012,16(18):3345-3348.

[30] Wang L, Tian J, Cui XQ, et al. Qiguan Yizhi. 2012;3(1):9-15.王雷,田军,崔先泉,等. 动态监测HLA Ⅰ类分子与降钙素原用于鉴别肾移植术后急性排斥反应与感染的价值[J]. 器官移植, 2012,3(1):9-15.

[31] Mao Q, Terasaki P I, Cai J, et al. Analysis of HLA class I specific antibodies in patients with failed allografts. Transplantation. 2007;83(1):54-61.

[32] He L, Ji G, DOng GL, et al. Zhonghua Waike Zazhi. 2009;47 (14): 1070-1074.贺梁,季刚,董光龙,等. 主要组织相容性复合体Ⅰ类样分子等位基因与活体小肠、肝、肾移植急性排斥反应相关性研究[J]. 中华外科杂志,2009,47(14):1070-1074.

[33] Morath C, Opelz G, Zeier M, et al. Prevention of antibody-mediated kidney transplant rejection. Transpl Int. 2012;25(6):633-645.

[34] Li ZF, Zhang S. Xian Jiaotong Daxue Xuebao:Yixueban. 2008; 29(1):1-6.李宗芳,张澍. 脾脏的基础研究进展与展望[J]. 西安交通大学学报:医学版, 2008,29(1):1-6.

[35] Bao B, Deili Geersang, Wu WH. Roulei Gongye. 2003;29 (7):20-22.包斌,德里格尔桑,吴文惠. 脾脏及其研究进展[J]. 肉类工业, 2003, 29(7):20-22.

[36] Zhang X, Li JP. Zhongguo Shuxue Zazhi. 2005;18(3): 197-199.章旭，李剑平. PCR-SSP在HLA低分辨中判型困难或无法判型的常见原因及解决策略[J]. 中国输血杂志,2005,18(3):197-199.

[37] Kanter Berga J, Sancho Calabuig A, Gavela Martinez E, et al. Pretransplant donor-specific HLA antibodies detected by single antigen bead flow cytometry: risk factors and outcomes after kidney transplantation. Transplant Proc. 2012;44(9): 2529-2531.

[38] Shao M, Ye Q, Ming Y, et al. Delayed graft function after DCD kidney transplantation: risk factors for and impact on transplantation. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2012;37(10):1045-1049.

[39] Ollinger R, Margreiter C, Bösmüller C, et al. Evolution of pancreas transplantation: long-term results and perspectives from a high-volume center. Ann Surg. 2012;256(5):780-787.

[40] Nowak I, Magott-Procelewska M, Kowal A, et al. Killer immunoglobulin-like receptor (KIR) and HLA genotypes affect the outcome of allogeneic kidney transplantation. PLoS One. 2012;7(9):e44718.